American Regent v. RK Pharma: Selenious Acid Patent Action Consolidated in 21 Days
American Regent, Inc. filed suit against RK Pharma, Inc. in the District of New Jersey asserting US12150957B2, a patent covering injectable selenious acid formulations used for intravenous selenium supplementation. The case was closed after just 21 days when the court ordered it consolidated into a related action, signalling parallel proceedings were already underway.
Fast-track consolidation signals a broader selenious acid patent dispute
On December 13, 2024, American Regent, Inc. — a specialty injectable pharmaceutical company — filed a patent infringement complaint against RK Pharma, Inc. in the U.S. District Court for the District of New Jersey. The asserted patent, US12150957B2 (application no. US18/672876), covers selenious acid injection formulations providing selenium at multiple concentration strengths: 60 mcg Se/mL in 10 mL and single-mL presentations, and 6 mcg Se/mL in a 2 mL vial.
The case closed on January 3, 2025 — just 21 days after filing — when the court issued a consolidation order directing that all future filings use a unified caption. This termination basis, ‘Case Consolidated,’ means the claims were not dismissed and no merits determination was made; rather, the action was folded into a pre-existing or simultaneously filed related proceeding, likely involving the same patent and additional generic filers challenging the same reference listed drug.
The 21-day lifespan is consistent with Hatch-Waxman ANDA litigation practice, where a brand plaintiff files separate suits against each ANDA filer and courts routinely consolidate parallel actions early to manage docket efficiency. The public record of this specific docket does not disclose the identity of the lead consolidated case, the number of co-defendants, or whether a 30-month stay has been triggered, leaving the full scope of American Regent’s enforcement campaign undisclosed from this case file alone.
Filing to Case Consolidated in 21 days
21 days — resolved before any substantive motion practice, well below the median ANDA/pharma patent litigation timeline
Case consolidated: what the court’s caption order means for both parties
Consolidation is procedural — the claims survive
A consolidation order under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single proceeding. Critically, no claims are dismissed and no merits ruling is entered. American Regent’s infringement allegations against RK Pharma continue under the lead docket caption. This is not a win or loss for either party — it is a court efficiency measure that typically precedes substantive litigation.
No merits adjudicationAmerican Regent preserves all infringement claims
Consolidation does not weaken the plaintiff’s position. American Regent retains its infringement claims under US12150957B2 and continues to pursue them in the consolidated action. In Hatch-Waxman contexts this structure is common when a brand company files suit against multiple generic ANDA applicants simultaneously, allowing coordinated discovery and claim construction across all defendants.
Claims intactRK Pharma now litigates alongside potential co-defendants
RK Pharma faces the same substantive infringement allegations but now within a multi-defendant consolidated framework. This can be strategically significant: shared prior art and invalidity arguments may reduce individual litigation costs, but the defendant also loses some control over pacing and strategy. The public record does not identify other defendants in the consolidated action, so the full competitive landscape of ANDA filers remains unclear.
Consolidated defenseMultiple generic challengers likely competing for selenium IV market entry
The consolidation pattern is consistent with a multi-filer Hatch-Waxman scenario targeting American Regent’s selenious acid reference listed drug. Intravenous selenium is a critical micronutrient in parenteral nutrition, representing a defensible specialty pharma niche. If a 30-month stay was triggered, generic market entry may be deferred into 2027. Competitors and formulary managers should monitor the consolidated docket for claim construction and summary judgment developments.
Parenteral nutrition IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty injectable pharmaceutical company — holder of US12150957B2 covering selenious acid formulationsSearch in Eureka ↗ |
| Defendant | RK PHARMA, INC. | Company | RK Pharma, Inc. — generic pharmaceutical manufacturer, alleged ANDA filer for selenious acid injectionSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order — directing that all filings in the consolidated action use a unified caption — is purely procedural in scope. It contains no finding of infringement, validity, or enforceability, and no damages assessment. The phrasing ‘WHEREFORE’ in the order’s caption direction is standard consolidation order language. For practitioners, this verdict text confirms the case was administratively closed rather than adjudicated, and substantive issues remain live in the consolidated proceeding.
US12150957B2 — Injectable Selenious Acid Formulations for IV Selenium Therapy
US12150957B2, filed under application number US18/672876, protects specific selenious acid injection formulations used to deliver selenium intravenously as part of parenteral nutrition regimens. The patent covers at least three commercial concentration/volume configurations: 60 mcg Se/mL in a 10 mL vial, 60 mcg Se/mL in a single-unit presentation, and 6 mcg Se/mL in a 2 mL vial. Selenium deficiency is a known risk in patients receiving long-term total parenteral nutrition, making this a clinically essential micronutrient product with a defined hospital formulary market.
The strategic value of US12150957B2 lies in its coverage across multiple commercial concentration strengths, which are directly tied to FDA-approved dosing for adult and pediatric parenteral nutrition. For American Regent, the patent creates a defensible exclusivity window for its selenium injection product line against generic ANDA challengers. The breadth of concentration coverage means potential generic entrants cannot easily reposition to a single dosage form without risking both patent infringement and loss of therapeutic equivalence ratings critical for formulary substitution.
Should your selenious acid injection product be cleared against US12150957B2?
Any pharmaceutical company developing, manufacturing, or filing an ANDA for a selenious acid injection product — particularly at concentrations of 60 mcg Se/mL or 6 mcg Se/mL — should treat US12150957B2 as a priority FTO target. American Regent’s immediate enforcement action against RK Pharma demonstrates that the patent holder monitors ANDA filings closely and acts within the Hatch-Waxman 45-day window. Waiting until after filing to assess FTO exposure is high-risk in this specific product category.
PatSnap Eureka’s FTO Search Agent can map the claim language of US12150957B2 against your formulation parameters, identify prior art that may support an invalidity argument, and surface related continuation or divisional applications that could extend the exclusivity footprint beyond this single patent. For parenteral nutrition product teams, Eureka can also identify whether the concentration and volume configurations in your ANDA align with or diverge from the patented claim elements, supporting a structured Paragraph IV or Paragraph III filing decision.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Patent Cases: Injectable Pharmaceutical Formulations in NJ
Explore related Hatch-Waxman ANDA cases in the District of New Jersey involving injectable pharmaceutical formulation patents and multi-defendant consolidation.
What this case signals for the parenteral nutrition and specialty injectable IP landscape
American Regent’s rapid multi-suit filing strategy suggests an active Hatch-Waxman enforcement campaign around its selenious acid portfolio.
Early consolidation is a signal of parallel ANDA filings — monitor the lead docket
When a pharma patent case closes this quickly via consolidation, it typically means other suits naming the same patent are already pending. IP teams should identify the lead consolidated case number and track it for claim construction orders and any 30-month stay determinations, which will govern generic entry timing across all ANDA filers.
US12150957B2 is actively enforced — FTO analysis is essential before ANDA filing
Any generic or 505(b)(2) applicant developing a selenious acid injection product should conduct a freedom-to-operate analysis against US12150957B2. The patent’s multiple concentration claims suggest broad coverage across common commercial strengths, and American Regent’s willingness to litigate immediately signals a low enforcement threshold.
American v RK — key questions answered
Case Consolidated means the court merged this action into a related proceeding, issuing a unified caption order. No merits ruling was entered — American Regent’s infringement claims under US12150957B2 remain active in the lead consolidated docket. The 21-day timeline from filing to consolidation is consistent with standard Hatch-Waxman multi-defendant case management practice.
The asserted patent is US12150957B2 (application US18/672876). It covers injectable selenious acid formulations used for intravenous selenium supplementation, specifically at concentrations of 60 mcg Se/mL (in 10 mL and single-unit presentations) and 6 mcg Se/mL in a 2 mL vial. These configurations correspond to commercially used parenteral nutrition micronutrient dosing strengths.
The public record of Case No. 2:24-cv-11122 does not explicitly confirm a 30-month stay. However, if American Regent filed within 45 days of receiving RK Pharma’s Paragraph IV certification notice — which the filing timeline is consistent with — a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) would automatically apply, potentially deferring generic market entry until mid-2027.
The case closed via a consolidation order, not a substantive ruling. In Hatch-Waxman litigation, brand companies often file parallel suits against multiple generic ANDA applicants and courts consolidate them for efficiency. The 21-day closure reflects administrative case management rather than any resolution of the underlying patent dispute, which continues in the lead consolidated action.
Consolidation does not eliminate or waive any of RK Pharma’s defenses. RK Pharma retains the ability to assert invalidity, non-infringement, and other defenses in the consolidated proceeding. Practically, a multi-defendant consolidated framework may allow shared invalidity arguments with co-defendants, potentially reducing litigation costs, though it may also reduce individual control over litigation strategy and scheduling.
PatSnap Eureka searches patents and litigation data to answer instantly.